Pediatrix Medical Group, Inc. (NYSE:MD) Shares Sold by Clark Estates Inc. NY

Clark Estates Inc. NY trimmed its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 7.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 317,000 shares of the company’s stock after selling 25,500 shares during the quarter. Clark Estates Inc. NY owned 0.37% of Pediatrix Medical Group worth $3,674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in MD. Aristeia Capital L.L.C. purchased a new position in shares of Pediatrix Medical Group in the second quarter worth $687,000. Vanguard Group Inc. raised its stake in Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after acquiring an additional 164,333 shares during the last quarter. Boston Partners lifted its position in Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after acquiring an additional 453,254 shares during the period. Rubric Capital Management LP grew its stake in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Pediatrix Medical Group by 14.1% in the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock valued at $5,953,000 after purchasing an additional 63,581 shares during the period. 97.71% of the stock is owned by institutional investors and hedge funds.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock opened at $14.76 on Wednesday. The business has a 50 day simple moving average of $13.01 and a 200-day simple moving average of $10.10. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. Pediatrix Medical Group, Inc. has a 12 month low of $6.62 and a 12 month high of $16.41.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the firm posted $0.29 earnings per share. Analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In related news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,808 shares of company stock worth $673,157 over the last quarter. 1.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on MD. Mizuho upped their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Jefferies Financial Group upped their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Truist Financial raised their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. StockNews.com lowered Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $16.10.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.